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Clinicopathologic features and epidermal growth factor receptor 
mutations associated with epithelial-mesenchymal transition in 
non-small cell lung cancer
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Small molecule inhibitors of epidermal growth factor receptor (EGFR), 
geﬁtinib and erlotinib, have been extensively studied in Non-small cell 
lung cancer (NSCLC) patients. The discovery of molecular biomark-
ers that identify the subgroups of NSCLC patients beneﬁting from 
EGFR tyrosine kinase inhibitor (TKI) has become an important area of 
investigation. Recently studies, which suggested that epithelial-mes-
enchymal transition (EMT) in tumors decreases cellular requirements 
for EGFR signaling pathway, provided a molecular signature (e.g. 
E-cadherin-positive) to deﬁne NSCLC patients most likely to respond 
to treatment targeted EGFR TKI. We performed immunohistochemi-
cal analyses of epithelial or mesenchymal phenotypic characteristics 
of unselected tumor specimens and compared EMT phenotypes with 
clinicopathologic features and EGFR genotypes. We observed 22 speci-
mens with E-cadherin-positive and 42 with vimentin-positive among 62 
NSCLC tumors. Kappa coefﬁcient analysis showed agreement with the 
EMT status of tumor specimens determined by E-cadherin staining and 
vimentin staining. Among NSCLC patients, E-cadherin-positive was 
statistically signiﬁcantly more frequent in EGFR mutants versus wild-
types (77.78% versus 18.18%; P<0.0001), and in females versus males 
(54.55% versus 25%; P=0.02). Logistic regression analysis conﬁrmed 
the correlation of EMT status with EGFR genotype (Odds ratio, 0.077; 
95% conﬁdence interval, 0.019 to 0.306; P=0.0003).It is concluded that 
EMT is associated with EGFR mutations in NSCLC and may account 
for primary resistance of NSCLC to EGFR TKI. 
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Estrogen and progesterone receptors in women with non-small-cell 
lung cancer: a potential therapeutic target?
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Background: A role of estrogens in the lung cancer development is 
suggested by gender-related differences in incidence and prognosis. 
Women affected by NSCLC show higher levels of sexual hormones than 
healthy females (Stabile LP et al, 2004). Also, the premenopausal status 
is associated with advanced stage, unfavourable histology and poorly 
differentiated tumors. The expression of estrogen receptor (ER) and pro-
gesterone receptor (PgR) could be involved in lung tumor progression 
and conﬂicting data emerged about the different expression of these re-
ceptors in the two genders. ERa is more likely to be expressed in women 
than men (Patel JD et al, 2005) and its overexpression is correlated 
with a poor outcome and with a smoking history (Kawai H et al, 2005). 
Preclinical studies reported an antiproliferative effect of antiestrogens 
in NSCLC cell lines and in vivo tumor xenografts but the potential for 
using ER inhibitors to treat NSCLC remains to be determined. Our goal 
was to assess ER and PgR expression in NSCLC females and to analyze 
their correlation with the clinical and pathological features in order to 
identify useful information for a therapeutic selection.
Methods: ERα and PgR expression was assessed by standard immu-
noistochemical methods using archival formalin-ﬁxed, parafﬁn-embed-
ded specimens. Univariated analysis of correlation between hormonal 
receptors and history of smoking, stage of disease and histology was 
performed with χ2 test. Kaplan-Meier survival curves were utilized to 
verify the potential impact of their expression on the clinical outcome.
Results: A total of 44 Italian women with a median age of 66 years 
(range 27-83) were evaluated. Their clinical-pathological features 
were: pre-menopausal/post-menopausal status 9/35, smokers/non 
smokers 18/26, adenocarcinoma/squamouscarcinoma/other histology 
34/2/8, stage I/II/III/IV 9/2/20/13, epidermal growth factor receptor 
(EGFR)+/EGFR- 31/13. 35 (80%) women received one or more lines 
of chemotherapy. PgR was expressed in 5 (11%) patients (pts) while no 
expression of ERα was found. No statistically signiﬁcant relationship 
emerged among PgR and ER expression and history of smoking, stage 
of disease and histology. No statistically signiﬁcant correlation was 
found between ER and PgR expression and survival.
Conclusions: Our results show an absent ERα expression and a low 
PgR expression in Western women affected by NSCLC. This suggests 
the need to better understand the biological pattern of NSCLC females, 
in order to potentially identify subsets of pts who could beneﬁt of an 
antiestrogen. This is particularly relevant considering the new data 
(Traynor AM et al, 2005) about the potential efﬁcacy of a combined 
treatment including both ER and EGFR inhibitors, based on their 
known cross-talking.
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Background: Thymic epithelial tumors (TET) have shown modest 
responses to standard chemotherapy. The aim of this study was to iden-
tify biological markers with potential predictive value. Five markers 
(CD20, HER2, c-kit and VEGFR1-2) were selected for evaluation in 
patients with advanced TET. 
Methods: 93 TET (WHO classiﬁed as 4 A, 25 AB, 9 B1, 26 B2, 11 
B3, 10C, 5 micronodular TET, 1 metaplasic thymoma and 2 carcinoids 
TET) including 3 paired primary/secondary tumor (B2/B3/C) were 
centrally reviewed. Each tumor was assessed by immunohistochemistry 
with a score from 0 to 3+.
Results: CD20 staining was positive (i.e. more than 10% positive cells) 
in 11 TET WHO AB (45%), while none of the others TET (WHO A, 
B1-3, C) were positive. C-kit was strongly expressed (3+, 100% of the 
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cells) in 7 TET WHO C (70%, including the paired primary/second-
ary tumor), a mild expression (1+ positivity on 100% of the cell) was 
observed in 2 TET WHO C, 1 TET WHO C was c-kit negative, all the 
A, AB, B1-3 WHO subtypes were negative. A nuclear HER2 staining 
was observed for 1 TET WHO A, 2 TET WHO AB, 3 TET WHO B2, 2 
TET WHO B3, and 1 micronodular TET. The 2 carcinoid tumors were 
strongly positive for c-kit and negative for CD20 and HER2.
Conclusions: CD20 and c-kit expression are restricted to TET WHO 
AB and C respectively. HER2 nuclear staining pattern is of unknown 
signiﬁcance. VEGFR 1-2 data will be presented at the meeting.
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Mechanisms controlling survival and induction of apoptosis 
following 12-lipoxygenase (LOX) inhibition in non small cell lung 
cancer (NSCLC)
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Background: Platelet-type 12-Lipoxygenase is an arachidonic acid 
metabolising enzyme that results in the formation of 12(S)-HETE. 
12(S)-HETE is proangiogenic, and has been shown to stimulate tumour 
cell adhesion, invasion and metastasis. Inhibitors of 12-LOX are cur-
rently undergoing extensive investigation, and a detailed examination of 
the effects of these agents in lung cancer is warranted. In this study we 
examined the expression proﬁle of 12-LOX in human lung cancer cell 
lines and resected tissue. We also examined the mechanisms responsible 
for apoptosis following selective inhibition of 12-LOX with baicalein. 
Methods: A549 (adenocarcinoma), SK-MES1 (squamous cell lung 
carcinoma), H460 and H647 (large cell lung carcinoma) were grown 
in serum depleted media (0.5%) and screened for 12-LOX expression 
by RT-PCR and western blot analysis. Cells were treated with baicalein 
(10uM), a selective inhibitor of 12-LOX, or 12(S)-HETE (100ng/ml) 
and cell survival / proliferation determined by BrdU assay. Apoptosis 
was determined using the multi-parameter apoptosis kit and In-cell 
Analyser, DNA laddering and also by FACS. Gene alterations follow-
ing 12-LOX inhibition in both A549 and SKMES-1 cells were assessed 
by quantitative PCR arrays and validated by RT-PCR. A panel of retro-
spective resected lung tumours were stained for 12-LOX expression by 
immunhistochemistry. 
Results: All lung cancer cells lines expressed moderate levels of plate-
let-type 12-LOX, which was reduced following treatment for 24h with 
increasing concentrations of baicalein. Baicalein decreased lung cancer 
survival in all cell lines, while 12(S)-HETE increased cellular prolif-
eration. Inhibition of 12-LOX induced apoptosis in a dose dependent 
manner, with decreased f-actin ﬁlaments and loss of mitochondrial 
mass potential. Induction of apoptosis was also conﬁrmed by DNA 
laddering and Annexin-V FACS labelling. QPCR array data implicated 
a number of genes regulating these effects which were validated by RT-
PCR, many of which control apoptosis and angiogenesis. The subset 
of genes downregulated included bcl-2, VEGF, integrin α2 and α4. 
12-LOX expression was observed in a variety of human lung cancers 
with different histological subtypes. We are currently silencing 12-LOX 
expression in these cells, using shRNA technology, to further examine 
these mechanisms.
Conclusions: 12-LOX is a survival factor in NSCLC. 12-LOX inhibi-
tion decreased NSCLC survival, inducing apoptosis through mecha-
nisms including downregulation of the bcl family of proteins, integrin 
receptor and angiogenic growth factors. Expression of 12-LOX in fresh 
resected and retrospective tissue suggests that inhibition of this enzyme 
is a potential therapeutic strategy in the treatment of NSCLC.
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SOCS1, SOCS3 and the transcription factor STAT1 in human lung 
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Background: Abberant DNA methylation, including hypermethylation 
of tumor suppressor genes or hypomethylation of oncogenes, is a hall-
mark of cancer and can be found in almost all cancer types. Informa-
tion about which methylation events are disease speciﬁc and also have 
effect on gene expression has a great potential in diagnostics and drug 
development. The aim of this study was to investigate the methylation 
status of the tumor suppressor genes SHP1, SHP2, SOCS1 and SOCS3 
and the transcription factor STAT1, and its effect on protein expression 
and tumor biology in lung cancer cell lines. Their activities are required 
for a functional regulation of cell growth and these genes have previ-
ously shown hypermethylation-associated tumor occurrence in several 
other types of cancers.
Methods: To study methylation patterns, bisulﬁte treatment of total 
DNA followed by PCR ampliﬁcation and Pyrosequencing® analysis 
was employed. The gene regions to be analyzed were determined ac-
cording to the regions that previously had shown aberrant methylation 
patterns in other types of cancers and psoriasis. Expression levels of the 
different proteins were evaluated by immunoprecipitation using anti-
bodies directed against each protein, followed by SDS-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) and Western blotting.
Five NSCLC cell lines and ﬁve SCLC were used in the studies.
Results: The methylation studies showed that the genes SHP1, SOCS1 
and SOCS3 are strongly methylated in some of the analyzed lung 
cancer (LC) cell lines, whereas SHP2 and STAT1 were not signiﬁcantly 
methylated in any cell line. The protein expression studies showed 
that the observed methylation levels in SHP1 were associated with a 
reduction of protein expression in the LC cell lines. Furthermore, the 
promoter region 1 (SHP1 A) of SHP1 demonstrated varying degrees of 
methylation throughout the LC cell lines, whereas promoter region 2 
(SHP1 B and C) was highly methylated in all cell lines. The epigenetic 
regulation of SHP1 has earlier been attributed to promoter region 2. 
In this study, on the other hand, the reduced protein expression seems 
to be associated with methylation in promoter region 1. SHP1 has 
earlier been reported to be methylated in promoter region 2 in normal 
epithelial cells, but to our knowledge there have been no reports on 
methylation in promoter region 1. The importance of the reduced SHP1 
expression in the regulation of proliferation, migration and invasion 
are being analyzed in the lung cancer cell lines and further data will be 
presented at the meeting.
Conclusions: The tumor suppressor genes SHP1, SOCS1 and SOCS3 
are highly methylated in lung cancer cell lines, making them potential 
diagnostic markers for lung cancer. Furthermore, methylation of the 
SHP1 promoter region 1 is associated with a strongly reduced protein 
